These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25828465)

  • 1. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report.
    Martin-Liberal J; Furness AJ; Joshi K; Peggs KS; Quezada SA; Larkin J
    Cancer Immunol Immunother; 2015 Jun; 64(6):765-7. PubMed ID: 25828465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
    Okamoto M; Okamoto M; Gotoh K; Masaki T; Ozeki Y; Ando H; Anai M; Sato A; Yoshida Y; Ueda S; Kakuma T; Shibata H
    J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
    Li S; Zhang Y; Sun Z; Hu J; Fang C
    Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
    Hofmann L; Forschner A; Loquai C; Goldinger SM; Zimmer L; Ugurel S; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Thomas I; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
    Eur J Cancer; 2016 Jun; 60():190-209. PubMed ID: 27085692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.
    Hansen E; Sahasrabudhe D; Sievert L
    Cancer Immunol Immunother; 2016 Jun; 65(6):765-7. PubMed ID: 27067877
    [No Abstract]   [Full Text] [Related]  

  • 9. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.
    Akturk HK; Alkanani A; Zhao Z; Yu L; Michels AW
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3589-3592. PubMed ID: 30124874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes.
    Jehl A; Cugnet-Anceau C; Vigouroux C; Legeay AL; Dalle S; Harou O; Marchand L; Lascols O; Caussy C; Thivolet C; Laville M; Disse E
    Diabetes Care; 2019 Oct; 42(10):2008-2010. PubMed ID: 31434650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
    Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
    Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
    Ivashko IN; Kolesar JM
    Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
    Zimmer L; Goldinger SM; Hofmann L; Loquai C; Ugurel S; Thomas I; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Forschner A; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
    Eur J Cancer; 2016 Jun; 60():210-25. PubMed ID: 27084345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.
    Rahman W; Conley A; Silver KD
    BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32616532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
    Gunjur A; Klein O; Kee D; Cebon J
    J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.
    Kao JC; Liao B; Markovic SN; Klein CJ; Naddaf E; Staff NP; Liewluck T; Hammack JE; Sandroni P; Finnes H; Mauermann ML
    JAMA Neurol; 2017 Oct; 74(10):1216-1222. PubMed ID: 28873125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
    Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
    BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L; Zou X; Chen Y; Bai X; Liang T
    Front Immunol; 2020; 11():2076. PubMed ID: 32973816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.